Immutep reports Q2 cash receipts from customers A$4,000

The company said, “During the quarter, Immutep (IMMP) continued to exercise prudent cash management as it advanced its clinical trial programs for efti and for IMP761. The Company is well funded with a strong cash and cash equivalent, and term deposit balance as at 31 December 2025 of approximately A$99.1M, which is in line with budget as at the beginning of FY2026, while progressing our clinical programs within announced timeframes. The total balance consists of a cash and cash equivalent balance of A$72.7M and bank term deposits totaling A$26.4M, which have been recognised as short-term investments due to having maturities of more than 3 months and less than 12 months. This amount is topped up by the upfront payment from Dr. Reddy’s received in January 2026, leading to a pro-forma balance of A$129.3M at the time of preparing this report…The current funds available to the Company at the time of this report provide an expected cash reach well into Q2 CY2027, not including receipt of any future potential milestone payments to be received.”